文献速递皮肤肿瘤

原发性皮肤外周T细胞淋巴瘤非特指型的临床病理与预后特征:EORTC多中心研究

Primary cutaneous peripheral T-cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico-pathological and prognostic features.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-12-22

欧洲癌症研究与治疗组织皮肤淋巴瘤工作组回顾性分析30例原发性皮肤外周T细胞淋巴瘤非特指型(PTL NOS)患者的33份活检,评估临床、组织学、免疫表型及结局。多数患者侵袭性病程,3年生存率61%、5年生存率54%,小至中等细胞形态预后较好,化疗最常用但孤立病灶可手术和/或放疗。

要点

  • 原发性皮肤PTL NOS侵袭性强,30例中33%死于淋巴瘤。
  • 肿瘤细胞小至中等形态者预后优于中等至大或大细胞。
  • 孤立病灶可考虑手术切除和/或放疗作为一线治疗。

核心结论

  • 原发性皮肤PTL NOS多数患者呈侵袭性病程,独立于初始表现、年龄和免疫表型。
  • 细胞形态学被确定为预后因素,小至中等细胞形态预后较好。
  • 数据提示需要更有效的治疗模式。

研究设计与样本

  • EORTC皮肤淋巴瘤工作组回顾性分析30例原发性皮肤PTL NOS患者的33份活检。
  • 由专家小组分析临床数据和组织病理学特征。

主要发现

  • 临床表现可为孤立或播散性快速生长的溃疡性肿瘤,或播散性丘疹结节性皮损。
  • 组织学多为真皮内弥漫或结节性浸润,常延伸至皮下组织,表皮趋向性罕见且轻微局限。
  • 不常见免疫表型常见,如CD3+/CD4-/CD8-和CD3+/CD4+/CD8+,18%病例肿瘤细胞异常表达B细胞标志物CD20。
  • 所有孤立肿瘤均位于四肢且GATA-3高表达,但与结局无关,不能作为预后因素。
  • 30例中10例(33%)在平均36个月随访(范围3-144个月)内死于淋巴瘤;3年生存率61%(CI 43-85%),5年生存率54%(CI 36-81%)。

关键数值与推荐

  • 细胞形态学:小至中等细胞形态预后优于中等至大或大细胞。
  • 年龄、性别、临床分期、CD4/CD8表型和GATA-3表达与预后无关。
  • 化疗是最常见治疗方式,但孤立病灶可考虑手术切除和/或放疗作为合适的一线治疗。

临床怎么用

  • 对孤立性皮肤PTL NOS病灶,可考虑手术切除和/或放疗作为一线治疗。
  • 评估肿瘤细胞形态学(小至中等 vs 中等至大/大)以辅助预后判断。
  • 多数患者需系统治疗,但化疗为最常见方式,需探索更有效方案。

局限性

  • 回顾性分析,样本量小(30例患者,33份活检)。
  • 专家小组病理评估,可能存在选择偏倚。
  • 随访时间变异大(范围3-144个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cutaneous peripheral T-cell lymphoma, not otherwise specified (PTL NOS) is an aggressive, but poorly characterized neoplasm. OBJECTIVES: The European Organization for Research and Treatment of Cancer cutaneous lymphoma taskforce (EORTC CLTF) investigated 33 biopsies of 30 patients with primary cutaneous PTL NOS to analyse their clinical, histological, immunophenotypic features and outcome. METHODS: Retrospective analysis of clinical data and histopathological features by an expert panel. RESULTS: Cutaneous PTL NOS manifested clinically either with solitary or disseminated rapidly grown ulcerated tumours or disseminated papulo-nodular lesions. Histologically, a mostly diffuse or nodular infiltrate in the dermis and often extending into the subcutis was found. Epidermotropism was rarely present and only mild and focal. Unusual phenotypes were frequent, e.g. CD3+ /CD4- /CD8- and CD3+ /CD4+ /CD8+ . Moreover, 18% of the cases exhibited an aberrant expression of the B-cell marker CD20 by the tumour cells. All solitary tumours were located on the limbs and presented a high expression of GATA-3 but this did not correlate with outcome and therefore could not serve as a prognostic factor. The prognosis was shown to be generally poor with 10 of 30 patients (33%) dying of lymphoma within the follow-up of 36 months (mean value; range 3-144). The survival rates were 61% after 3 years (CI, 43-85%) and 54% after 5 years (CI, 36-81%). Small to medium-sized morphology of tumour cells was associated with a better outcome than medium to large or large tumour cells. Age, gender, clinical stage, CD4/CD8 phenotype and GATA-3 expression were not associated with prognosis. Chemotherapy was the most common treatment modality, but surgical excision and/or radiotherapy may represent an appropriate first-line treatment for solitary lesions. CONCLUSIONS: Cutaneous PTL NOS shows an aggressive course in most patients independent of initial presentation, age and phenotype. Cytomorphology was identified as a prognostic factor. The data indicate a need for more effective treatment modalities in PTL NOS.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Kempf W, Mitteldorf C, Battistella M, et al. Primary cutaneous peripheral T-cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico-pathological and prognostic features. J Eur Acad Dermatol Venereol. 2020. PMID: 32997839. doi:10.1111/jdv.16969

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。